A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
暂无分享,去创建一个
M. Rieder | Joshua D. Smith | G. Cooper | D. Roden | M. Ritchie | Julie A. Johnson | A. Rettie | D. Veenstra | T. Langaee | C. Stein | I. Stanaway | H. Feng | U. Schwarz | C. Stein
[1] M. Rieder,et al. Estimating coverage and power for genetic association studies using near-complete variation data , 2008, Nature Genetics.
[2] Joshua M. Korn,et al. Mapping and sequencing of structural variation from eight human genomes , 2008, Nature.
[3] Y. Turpaz,et al. CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.
[4] Dan M Roden,et al. Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.
[5] Dolores Corella,et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.
[6] Brian F. Gage,et al. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues , 2008, Journal of Thrombosis and Thrombolysis.
[7] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[8] M. Rieder. Pharmacogenetics of warfarin treatment for potential clinical application , 2007 .
[9] M. Rieder,et al. γ‐Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose , 2007, Journal of thrombosis and haemostasis : JTH.
[10] Pauline C Ng,et al. Power to Detect Risk Alleles Using Genome-Wide Tag SNP Panels , 2007, PLoS genetics.
[11] M. Stephens,et al. Imputation-Based Analysis of Association Studies: Candidate Regions and Quantitative Traits , 2007, PLoS genetics.
[12] Dana C Crawford,et al. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. , 2007, Pharmacogenomics.
[13] Ingrid Glurich,et al. Evaluation of Genetic Factors for Warfarin Dose Prediction , 2007, Clinical Medicine & Research.
[14] D. Conrad,et al. Global variation in copy number in the human genome , 2006, Nature.
[15] B. Horne,et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.
[16] P. Deloukas,et al. Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.
[17] Guoying Tai,et al. The pharmocogenomics of warfarin: closing in on personalized medicine. , 2006, Molecular interventions.
[18] Tom Schalekamp,et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation , 2006, Clinical pharmacology and therapeutics.
[19] Julie A. Johnson,et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.
[20] Dana C Crawford,et al. The patterns of natural variation in human genes. , 2005, Annual review of genomics and human genetics.
[21] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[22] M. Stephens,et al. Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-data Imputation , 2022 .
[23] M. Margaglione,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.
[24] F. Martinez,et al. Automated high-throughput sex-typing assay. , 2004, BioTechniques.
[25] Sivakumar Gowrisankar,et al. Pattern of sequence variation across 213 environmental response genes. , 2004, Genome research.
[26] Samuel Z Goldhaber,et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms , 2004, Thrombosis and Haemostasis.
[27] Andreas Fregin,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.
[28] A. Khvorova,et al. Identification of the gene for vitamin K epoxide reductase , 2004, Nature.
[29] Pak Chung Sham,et al. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..
[30] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[31] Kaoru Kobayashi,et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.
[32] A. Rettie,et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin , 1999, Epilepsy Research.
[33] S. Fihn,et al. The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.